Biochemistry

Which are the Top 3 Markets for Lab Automation ? – PharmiWeb.com

Synopsis of the Lab Automation Market

Future Market Insights offers a 10-year forecast on the lab automation market between 2017 and 2027. In terms of value, the lab automation market is expected to register a CAGR of 9.6% during forecast period. This lab automation market study demonstrates the global market dynamics and trends across various regions such as North America, Latin America, Western Europe, Eastern Europe, APEJ, Middle East & Africa, and Japan, which influence the current nature and future status of the lab automation market over the forecast period.

Lab Automation Market: Report Description

This research report provides a detailed analysis of the lab automation market, and offers insights on various factors. This lab automation market study provides a comprehensive assessment of stakeholder strategies and imperatives for succeeding in the business. The stakeholders in this lab automation market include healthcare automation providers, hospitals, pharmacies, and clinics. The lab automation report segregates the market based on component: devices and software; application, and end users across different regions, worldwide.

The increasing demand for technically advanced automated lab devices and platforms in various verticals such as biochemistry, hematology, microbiology, immunology, and molecular biology, for improved and accurate diagnosis, is anticipated to drive the growth of the lab automation market over the forecast period. Advancements in lab automation allow process standardization, which, in turn, decreases the frequency of outliers and errors, and is a key factor expected to propel the growth of the lab automation market.

The report starts with an overview of the global lab automations market in terms of value. In addition, this section includes the analysis of key trends, drivers, and restraints that are influencing the lab automation market. An impact analysis of key growth drivers and restraints is included in the lab automations market report to facilitate clients with crystal-clear decision-making insights.

To Get Sample Copy of Report visit @https://www.futuremarketinsights.com/reports/sample/rep-gb-394

The global lab automation market is categorized on the basis of component, application, end user, and region. On the basis of component, the lab automation market is segmented into devices and software. Further, the devices segment has been segmented into six categories biochemistry devices, molecular devices, hematology devices, immunology devices, microbiology devices, and others. The software segment is bifurcated into two segments scheduling software and momentum integration software.

On the basis of application, the lab automation market is segmented into life sciences research & development, drug-discovery, and diagnostics. In terms of revenue share, the life sciences R&D segment dominated the global lab automation market in 2017, and is expected to do so throughout the forecast period. The diagnostics application segment is anticipated to expand at the fastest CAGR over the forecast period.

On the basis of end user, the global lab automation market is segmented into pharmaceutical companies, hospitals and diagnostic centers, educational institutions, contract research organizations (CROs), and research institutes. The hospitals and diagnostic centers segment currently accounts for the highest revenue in the lab automation market, due to the increasing usage of automation devices in hospitals and diagnostic centers in developed countries.

The next section highlights a detailed analysis of the lab automation market across various countries in different regions. It provides a market outlook for 20172027, and sets the forecast within the context of the lab automation market to include the latest technological developments as well as service offerings in the market. This lab automation market study discusses key trends within countries contributing to the growth of the lab automation market, as well as analyses degrees at which the drivers are influencing this market in each region. Key regions and countries assessed in the lab automation report include North America (U.S. and Canada), Latin America (Brazil, Mexico, Argentina and the Rest of Latin America), Western Europe (Germany, UK, France, Italy, Spain, Nordic, and the Rest of Europe), Eastern Europe (Russia, Poland, and the Rest of Eastern Europe), APEJ (India, China, ASEAN, Australia and New Zealand, and the Rest of APEJ), Japan, and MEA (South Africa, GCC Countries, and Rest of MEA).

The report evaluates the present scenario and growth prospects of the lab automation market across various regions, globally, for the period 20172027. We have considered 2016 as the base year, and provided data for the remaining 12 months. The forecast presented in the lab automation market report assesses the total revenue by value across the market. To offer an accurate forecast, we started by sizing the current lab automation market, which forms the basis of how the lab automation market will develop in the future. Given the characteristics of the lab automation market, we have triangulated the outcome of the analysis of different types and verticals based on technology trends.

In addition, it is imperative to note that, in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse on the basis of key parameters such as Year-on-Year (Y-o-Y) growth, to understand the predictability of the lab automation market, and to identify the right opportunities across the market.

In the final section of the lab automation market report, we have included a competitive landscape to provide clients a dashboard view based on the categories of providers in the value chain, their presence in the lab automation portfolio, and key differentiators. This section is primarily designed to provide clients an objective and detailed comparative assessment of key providers specific to a market segment in the lab automation value chain, as well as the potential players for the same. Audiences of the lab automation market report can gain segment-specific vendor insights to identify and evaluate key competitors based on an in-depth assessment of their capabilities and success in the marketplace. Detailed profiles of lab automation providers are also included in the scope of the report to evaluate their long-term and short-term strategies, key offerings, and recent developments in the lab automation space. Some of the key competitors covered in the lab automation market are Abbott Laboratories, Agilent Technologies, Perkin Elmer, Inc, Thermo Fisher Scientific, Inc, Siemens Healthcare, Danaher Corporation, Becton, Dickinson and Company, and Transcriptic, Inc.

For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-394

Key Segments Covered in the Lab Automation Market Report

And many more

Explore Wide-ranging Coverage of FMIs Healthcare Landscape

Transradial Closure Devices MarketFMIs analysis gives an insight into key market trends, strategies, regional players and various segments on the basis of form, type, application and region.

Fiducial Markers MarketFind insights into global market scenario and segmentation on the basis of ingredients, application, source and region.

Mammalian Transient Protein Expression MarketFMIs report highlights parent market trends and strategies in the market with segments and dynamics through the forecast period (2020-2030).

ABOUT FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMIs latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Mr. Abhishek Budholiya

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: sales@futuremarketinsights.com

For Media Enquiries: press@futuremarketinsights.com

Report: https://www.futuremarketinsights.com/reports/lab-automation-market

Read more:
Which are the Top 3 Markets for Lab Automation ? - PharmiWeb.com

Biochemistry

Cidara Therapeutics Announces Key Additions to its Board of Directors – GlobeNewswire

SAN DIEGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of internationally-renowned molecular biologist Bonnie Bassler, Ph.D., and seasoned life science executive Carin Canale-Theakston to its board of directors.

We are pleased to welcome Dr. Bassler and Ms. Canale-Theakston to our board of directors, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. We look forward to leveraging Dr. Basslers expertise in molecular biology and vast experience serving on boards across academia and the biotech industry and Ms. Canale-Theakstons 25+ years of experience spearheading complex business and communication strategies for life science companies. Their combined expertise will be of tremendous value as we advance our novel antifungal, rezafungin, currently in pivotal Phase 3 trials, towards filing, and our antiviral conjugate (AVC) influenza program to IND filing.

Dr. Bassler is a Howard Hughes Medical Institute Investigator and the chair of the department of molecular biology and the Squibb professor in molecular biology at Princeton University. She currently serves as a board member of Regeneron, Kaleido Biosciences and Royalty Pharma. Dr. Bassler has previously served as a board member of Sanofi, the American Association for the Advancement of Science, the National Science Foundation and the American Academy of Microbiology, where she also served as the president. Dr. Basslers scientific honors include a MacArthur Foundation Fellowship, the Lounsbery Award and the Shaw Prize for Life Science and Medicine. She holds a B.S. in biochemistry from the University of California-Davis and a Ph.D. in biochemistry from the John Hopkins University.

Ms. Canale-Theakston is the chief executive officer and founder of Canale Communications, a life science communications firm. Over the course of her career, she has led corporate strategy and corporate communications for more than 300 life science companies of varying sizes and stages. Ms. Canale-Theakston serves as vice chair of the board of directors for Biocom California, and co-chairs both the Biocom Capital Development Committee and the boards nominating and governance committee. She has received a multitude of awards, including the E&Y Entrepreneur of the Year award for 2019, California Assemblywoman Toni G. Atkins Woman of the Year for the 78th assembly district and San Diego 500 list of influential business leaders in life sciences from 2016-2020. Ms. Canale-Theakston previously served as president of the life sciences division of international public relations firm, Porter Novelli. She holds a B.S. in marketing & communications from the University of Tulsa.

About RezafunginRezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).

About Cloudbreak AVCsCidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak antiviral platform that couple potent antivirals to a human antibody fragment. These long-acting, antiviral conjugates (AVCs) directly inhibit viral proliferation while simultaneously engaging the immune system. AVCs are initially being studied for the prevention and treatment of seasonal and pandemic influenza, with the potential to deliver universal protection for an entire flu season with a single dose. Cidara is also advancing preclinical and discovery AVC programs to target other life-threatening viruses, such as RSV, HIV and CoV, including COVID-19.

About Cidara TherapeuticsCidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Companys portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidaras proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit http://www.cidara.com.

Forward-Looking StatementsThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as anticipates, expect, may, plan or will. Forward-looking statements in this release include, but are not limited to, statements related to the anticipated contributions from Dr. Bassler and Ms. Canale-Theakston, and the potential for Cidaras therapeutics to transform the standard of care for patients facing serious fungal or viral infections, as well as the potential for AVCs to deliver universal protection for an entire flu season with a single dose. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidaras clinical trials, impacts of the COVID-19 pandemic on patient enrollment or other obstacles to the development of rezafungin and advancement of Cidaras other development programs. These and other risks are identified under the caption Risk Factors in Cidaras most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on managements assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com

MEDIA CONTACT:Karen OShea, Ph.D.LifeSci Communications(929) 469-3860koshea@lifescicomms.com

More:
Cidara Therapeutics Announces Key Additions to its Board of Directors - GlobeNewswire

Genetics

Press Registration Is Now Open for the 2021 ACMG Annual Clinical Genetics Meeting – A Virtual Experience – PRNewswire

BETHESDA, Md., Jan. 27, 2021 /PRNewswire/ --The ACMG Annual Clinical Genetics Meeting will be a fully virtual meeting in 2021 and continues to provide groundbreaking research and the latest advances in medical genetics, genomics and personalized medicine. To be held April 1316, experience four days of professional growth, education, networking and collaboration with colleagues from around the world and discover what's shaping the future of genetics and genomics, including several sessions on COVID-19. The 2021 ACMG Meeting Virtual Experience is designed to offer a variety of engaging and interactive educational formats and types of sessionsfrom Scientific Sessions and Workshops to TED-Style Talks, Case-based Sessions, Platform Presentations and Short Courses. The 2021 ACMG Meeting Virtual Experience has something for everyone on the genetics healthcare team and will be available to participate in from the convenience of your home or office.

Interview those at the forefront in medical genetics and genomics, connect with new sources, and get story ideas on the clinical practice of genetics and genomics in healthcare today and for the future. Learn how genetics and genomics research is being integrated and applied into medical practice. Topics include COVID-19, gene editing, cancer genetics, molecular genomics, exome sequencing, pre- and perinatal genetics, diversity/equity and inclusion, biochemical/metabolic genetics, genetic counseling, health services and implementation, legal and ethical issues, therapeutics and more.

Credentialed media representatives on assignment are invited to cover the ACMG Annual Meeting A Virtual Experience on a complimentary basis. Contact Kathy Moran, MBA at [emailprotected]for the Press Registration Invitation Code, which will be needed to register at http://www.acmgmeeting.net.

Abstracts of presentations will be available online in February.

A few 2021 ACMG Annual Meeting highlights include:

Program Highlights:

Two Short Courses Available Starting on Tuesday, April 13:

Cutting-Edge Scientific Concurrent Sessions:

Social Media for the 2021 ACMG Meeting Virtual Experience: As the ACMG Annual Meeting approaches, journalists can stay up to date on new sessions and information by following the ACMG social media pages on Facebook,Twitterand Instagramand by usingthe hashtag #ACMGMtg21 for meeting-related tweets and posts.

The ACMG Annual Meeting website has extensive information at http://www.acmgmeeting.net and will be updated as new information becomes available.

About the American College of Medical Genetics and Genomics (ACMG) and the ACMG Foundation for Genetic and Genomic Medicine (ACMGF)

Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical society dedicated to improving health through the clinical practice of medical genetics and genomics and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for more than 2,400 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG's mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. Four overarching strategies guide ACMG's work: 1) to reinforce and expand ACMG's position as the leader and prominent authority in the field of medical genetics and genomics, including clinical research, while educating the medical community on the significant role that genetics and genomics will continue to play in understanding, preventing, treating and curing disease; 2) to secure and expand the professional workforce for medical genetics and genomics; 3) to advocate for the specialty; and 4) to provide best-in-class education to members and nonmembers. Genetics in Medicine, published monthly, is the official ACMG journal. ACMG's website (www.acmg.net) offers resources including policy statements, practice guidelines, educational programs and a 'Find a Genetic Service' tool. The educational and public health programs of the ACMG are dependent upon charitable gifts from corporations, foundations and individuals through the ACMG Foundation for Genetic and Genomic Medicine.

Kathy Moran, MBA[emailprotected]

SOURCE American College of Medical Genetics and Genomics

http://www.acmg.net

See the original post:
Press Registration Is Now Open for the 2021 ACMG Annual Clinical Genetics Meeting - A Virtual Experience - PRNewswire

Genetics

Researchers develop new computational method for studying genetic and environmental interactions – News-Medical.Net

Researchers at Weill Cornell Medicine and Cornell University's Ithaca campus have developed a new computational method for studying genetic and environmental interactions and how they influence disease risk.

The research, published Jan. 7 in The American Journal of Human Genetics, makes the process of finding these interactions much less difficult and demonstrates their importance in determining body mass index and diabetes risk.

"Our study demonstrates that your genes matter and the environment matters and that the interaction of the two can increase risk for disease," said co-senior author, Dr. Olivier Elemento, who is professor of computational genomics in computational biomedicine, professor of physiology and biophysics, associate director of the HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, and director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine.

Typically, studying gene-environment interactions creates a huge computational challenge, said lead author Andrew Marderstein, a doctoral candidate in the Weill Cornell Graduate School of Medical Sciences whose research was conducted both in Dr. Elemento's lab in New York City and Dr. Andrew Clark's lab in Ithaca, enabling him to have immediate access to computational biology and population health expertise.

"Genotype-environment interaction can be thought of as the situation where some genotypes are much more sensitive to environmental insults than others," said Dr. Clark, co-senior author and Jacob Gould Schurman Professor of Population Genetics in the Department of Molecular Biology and Genetics in the College of Arts & Sciences and a Nancy and Peter Meinig Family Investigator at Cornell University. "These are exactly the cases where changes in the diet or other exposures might have the biggest improvement in health, but only for a subset of individuals."

The millions of genetic variants, or inherited genetic differences found between individuals in a population, and different lifestyle and environmental factors, such as smoking, exercise, different eating habits, can be analyzed for combined effects in numerous ways.

When researchers test for gene-environment interactions, they typically analyze millions of data points in a pairwise fashion, meaning they assess one genetic variant and its interaction with one environmental factor at a time. This type of analysis can become quite labor intensive, said Marderstein.

The new computational method prioritizes and assesses a smaller number of variants in the genome--or the complete set of genetic material found in the body--for gene-environment interactions.

We condensed a problem with analyzing 10 million different genetic variants to essentially analyzing only tens of variants in different regions of the genome."

Andrew Marderstein, Study Lead Author and Doctoral Candidate and Graduate, School of Medical Sciences , Weill Cornell Medicine

While a standard genetic association study might look at whether a single genetic variant could lead to an average change in body mass index (BMI), this study assessed which genetic variants were associated with individuals being more likely to have a higher BMI or lower BMI.

The researchers found that looking for sections of DNA associated with the variance in a human characteristic, called a variance quantitative trait locus or vQTL, enabled them to more readily identify gene-environment interactions. Notably, the vQTLs associated with body mass index were also more likely to be associated with diseases that have large environmental influences.

Another area of study where the new computational method might useful is determining how an individual might respond to a specific drug based on gene-environment interactions, said Marderstein. Analysis of social determinants of health, meaning a person's environmental and social conditions, such as poverty level and educational attainment, is a third area that the researchers are interesting in pursuing, according to Dr. Elemento.

Overall, scientists in the precision medicine field are realizing they can sequence a person's DNA, in addition to assessing environmental factors such air quality and physical activity, to better understand whether the individual is at risk of developing a specific disease.

"The idea down the line is to use these concepts in the clinic," said Dr. Elemento. "This is part of the evolution of precision medicine, where we can now sequence somebody's genome very easily and then potentially analyze all of the variants in the genetic landscape that correlate with the risk of developing particular conditions."

Go here to read the rest:
Researchers develop new computational method for studying genetic and environmental interactions - News-Medical.Net

Genetics

Animal Genetics Market Forecast to 2027 – COVID-19 Impact and Global Analysis By Product, Genetic Material, and Services and Geography. -…

New York, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Animal Genetics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product, Genetic Material, and Services and Geography." - https://www.reportlinker.com/p06010023/?utm_source=GNW However, the market is likely to get impacted by the limited number of skilled professionals in veterinary research and stringent government regulations for animal genetics during the forecast period.

The branch of genetics that deals with the study of gene variation and inheritance in companion, domestic and wild animals is called as animal genetics.Animal genetics are used for genetic trait testing, DNA testing, and genetic disease treatment.

Animal genetics is one of the best mainstays of livestock development (alongside animal nutrition, animal health, and husbandry concerns such as housing). According to the Food and Agriculture Organization of the United Nations, it is a wide field, ranging from characterization to maintenance to genetic improvement, and involves activities at local, national, regional, and global scales.Increasing population and rapid urbanization across the world has resulted in growing preference for animal derived food products such as dairy products and meat that contain high protein.The demand for animal derived proteins and food products, which, in turn drives the growth of animal genetics market.

Growing focus on developing superior animal breeds using genetic engineering to obtain high reproduction rates for large-scale production of modified breeds is expected to drive animal genetics market during the forecast period.Based on product, the market is segmented into poultry, porcine, bovine, canine, and others.The porcine segment held the largest share of the market in 2019, whereas the same segment is anticipated to register the highest CAGR in the market during the forecast period.

Growth of this segment is attributed to rise in production of porcine and increase in pork consumption across the globe.Based on genetic material, the market is segmented into semen and embryo. The embryo segment held the largest share of the market in 2019, and the semen segment is anticipated to register the highest CAGR in the market during the forecast period.COVID-19 pandemic has become the most significant challenge across the world.This challenge would be frightening, especially in developing countries across the globe, as it may lead to reducing imports due to disruptions in global trade, which further increases the shortages of meat and dairy product supplies, resulting in a considerable price increase.

Asian countries such as China, South Korea, and India are severely affected due to COVID-19 outbreak.The World Health Organization, Food and Drug Administration, American Pet Products Association, American Veterinary Medical Cattle Health, and Welfare Group for Disease Control and Prevention are among the major primary and secondary sources referred for preparing this report.Read the full report: https://www.reportlinker.com/p06010023/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Go here to see the original:
Animal Genetics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product, Genetic Material, and Services and Geography. -...

Genetics

Digbi Health’s gut-microbiome and genetic-based obesity management program now allows 60,000 Doctors and Providers in Blue Shield of California’s…

MOUNTAIN VIEW, Calif., Jan. 26, 2021 /PRNewswire/ --Digbi Health, the first company with a clinically proven genetics and gut-microbiome based program to safely and sustainably treat and manage obesity and associated inflammatory gut, skin and cardiometabolic health issues, is now available to Blue Shield of California members, as a fully covered program, on the health plan'sWellvolution platform.

It's the first time over 60,000 physicians and clinicians practicing in California in the Blue Shield of California's network can prescribe a weight-loss program personalized on a person's genetic, gut microbiome and lifestyle. Through the Digbi Health solution, patients are supported by a team of caregivers, led by a physician and care experts trained in nutrition, cognitive behavior therapy, genetics and gut microbiome. Blue Shield of California offers access to Digbi Health through the Wellvolution platform as a fully covered program to members who qualify.

The Digbi Health Precision Care Network (PCN) is a network of physicians practicing precision medicine. As part of that network, physicians get marketing resources to educate their patients about Digbi Health on the Wellvoution platform, access to their patient's dashboard, with patient approval, and additional support from the Digbi Health care concierge team to support their patients between visits to help improve patient outcomes. Digbi Health program members without a physician can also get referred to a specialist in the PCN.

"The development of cardiovascular disease is a matter of genetic predisposition and gut microbiome composition interacting with acquired conditions, and factors such as diet, exercise, and exposure to damaging elements," said Cynthia Thaik, MD. Harvard-trained cardiologist at the Holistic Healing Heart Center and Digbi Health PCN member.

"I have already prescribed Digbi Health to a patient covered by Blue Shield of California for pre-diabetes and hypertension," she added.

Blue Shield of California is taking the lead on personalized and preventive care for their members.

Among participants participating in Wellvolution:

"We are an innovative telehealth company that supports overburdened physicians by redefining care for 100 million Americans who struggle under one-size-fits-all digital health programs, weight loss diets and stigma of "poor self-control" while fighting obesity and associated inflammatory comorbidities," said Ranjan Sinha, CEO and founder of Digbi Health.

About Digbi Health Precision Care NetworkOur network includes healthcare providers from all specialties and practice settings throughout the U.S., including bariatric surgeons, internal medicine, family medicine, chiropractitioners, nutritional experts, and others in the lifestyle and integrative medicine space using genetics, nutrigenomics, gut microbiome and lifestyle risk to treat the complexity of the multifactorial disease of obesity and its' related medical conditions. Providers can sign-up to the network at no charge here.

About Digbi HealthDigbi Health is a first-of-its-kind precision digital therapeutics company that offers a prescription-grade digitally enabled personalized obesity and obesity related gut, skin disorders, hypertension and other cardiometabolic health management programs based on an individual's gut biome, genetic risks, blood markers, and lifestyle factors. Digbi Health and members of its physician network are committed to empowering people to take control of their own health and wellness. Digbi Health is prescribed by doctors, health care providers, and insurance companies.

SOURCE Digbi Health

See more here:
Digbi Health's gut-microbiome and genetic-based obesity management program now allows 60,000 Doctors and Providers in Blue Shield of California's...

Genetics

Cambridge-based Sano Genetics gets a capital injection of 2.5M to offer free at-home DNA testing kits for those affected by Long COVID – UKTN (UK…

Sano Genetics, a Cambridge-based startup with an aim to support personalised medicine research by increasing participation in clinical trials and guiding patients all through the process has recently grabbed 2.5M seed funding from a slew of investors.

The financing round was led by Episode1 Ventures along with participation from Cambridge Enterprise, Seedcamp, January Venture and a slew of angel investors from UK, Europe and US. Previously, Sano Genetics raised 500K pre-seed funding in 2018.

The latest funding round includes a grant from Innovate UK, which will cover the cost of free at-home DNA testing kits for 3,000 people affected by Long Covid. Also, the investment will be used for the continuous development of its private-by-design tech platform, which gives full control and transparency for users regarding how and where their personal data is used by researchers.

Chief operating officer of Sano Genetics, Charlotte Guzzo, explained: This tranche of funding will help us further develop the end-to-end experience for the many people keen to contribute to personalised medical research, including clinical trials of potentially life-changing medicines and, in doing so, improve the outlook for people living with chronic and often debilitating conditions.

Besides the funding, Sano Genetics partnered with Genomics England to develop software that will be used for national-scale precision medicine initiatives. It will improve the participants experience in research. This software will add a vital layer of information reported directly by participants including daily symptom tracking or via wearable devices monitoring activity or sleep.

Sano Genetics was founded in 2017 by Charlotte Guzzo, Patrick Short and William Jones while pursuing genomics at Cambridge University. They observed, first hand, the high failure rate of clinical trials and the poor experience for those taking part. The startups digital platform and at-home genetic testing capabilities are already empowering greater participation in crucial research into multiple sclerosis, ankylosing spondylitis, NAFLD, and ulcerative colitis. Also, it plans for a research programme for Parkinsons disease for late this year.

Original post:
Cambridge-based Sano Genetics gets a capital injection of 2.5M to offer free at-home DNA testing kits for those affected by Long COVID - UKTN (UK...

Genetics

A&M team’s research on rabbits leads to genetic breakthrough – Texas A&M The Battalion

Even with shared ancestry, domesticated and wild animals look different, but according to a recent study, their differences stretch far beyond their appearances.

In a study led by Leif Andersson, a professor at the Texas A&M College of Veterinary Medicine & Biomedical Sciences, or CVMBS, he and his team discovered there were changes in gene expression between the brains of domesticated and wild rabbits, as mentioned in Texas A&M Today.

Domestication is a very important development which happened during human history so there has been a lot of interest to try to understand what genetic changes have happened during domestication, Andersson said. So, how could we transform a wild species into a domesticated species?

Andersson said his team chose rabbits rather than other domesticated animals, like dogs and goats, as rabbits were more recently domesticated which makes genetic and structural changes more evident.

The team started by DNA sequencing wild rabbits and domestic rabbits from different breeds and then compared the different sequences in their genomes, Andersson said.

The most consistent differences we saw between wild and domestic was changes in gene frequencies in genes related to brain development, Andersson said.

The next step was looking at the morphology in the rabbits brain. Andersson said they found structural changes in the brain, specifically in the amygdala, which is the part of the brain involved in how animals respond to fear. Ultimately, the expression of dopamine changed in the amygdala, said Andersson.

It turned out that domestic rabbits amygdala had shrunk in size, Andersson said. There is a functional difference in how the amygdala functions in the domestic rabbit.

Todd OHara, the Veterinary Integrative Sciences department head, said Andersson did a great job linking genetics with function, as he looked at how genes turned on and off and then linked it to morphological processes.

In some cases in genetic studies, we often end up with what we call transcriptomic data, OHara said. What we see there is just results from what genes were upregulated and which genes are downregulated, and then were left with that. In this case, they were able to make linkages..

The teams findings make a significant contribution to the understanding of how the changes in brain architecture and gene expression affect animal behavior and lead to altered fear responses, Brian Davis, a professor in the CVMBS, said.

Since dopamine is intimately involved with the sense of well-being and reward behavior, this finding is consistent with the physiological response of reduced fear, Davis said.

While the data-intensive study involved a large amount of mathematical processing, Andersson and his teams diligence ultimately led to a significant finding.

It gives the first clue to what type of changes in gene expression is associated with the development of tameness, so it would be very interesting to follow up with this in other species and see if this is a common theme, said Andersson. Its a good step towards understanding [how] domestication has affected brain function in domestic animals.

View original post here:
A&M team's research on rabbits leads to genetic breakthrough - Texas A&M The Battalion

Genetics

‘Sticking with what we have and selecting superior genetics seen as the way forward’ – Agriland

Sticking with what we have and selecting for superior genetics rather than importing genetics from New Zealand is seen as the way forward for Irish sheep farmers, according to Nicola Featherstone.

Nicola was speaking at the first of two virtual Teagasc Sheep Conferences which were held yesterday evening (Tuesday, January 26).

Teagasc Walsh Scholar Nicola gave an update on the INZAC trial in Teagasc Athenry, Co. Galway, which compares 1-star and 5-star Irish ewes with elite New Zealand ewes.

One question put to Nicola during yesterdays session was how relevant did she think New Zealand sheep are in an Irish context and if they are far superior to what we have here in Ireland?

She explained: During my time in New Zealand, along with visiting a number of farms, I also collaborated with a consultancy company and over there we generated a model and that model looked at all different scenarios that we could put into practice here in Ireland.

For example, whether or not we would look at importing New Zealand genetics or should we stick with what we have here in Ireland or maybe a mixture of both.

From looking at the results, it showed that the benefit, in terms of genetics and economics, would be greater for the Irish industry if we stuck with what we have rather than importing New Zealand genetics, as long as we source our genetics from more progressive breeders.

So, essentially, it means that we need commercial farmers to drive demand towards sourcing animals of superior genetics.

If we stick with the system we have which identifies the elite animals, in terms of being 5-stars, then this is the best way forward for Irish sheep farmers.

RELATED STORIES

The rest is here:
'Sticking with what we have and selecting superior genetics seen as the way forward' - Agriland

Genetics

Partners in Crime: Genetic Collaborator May Influence Severity of the Rare Disease, NGLY1 – Newswise

Newswise In 2012, four-year-old Bertrand Might became the first-ever patient diagnosed with a rare genetic disorder called N-glycanase (NGLY1) deficiency. The discovery of this condition and Bertrands diagnosis allowed doctors to look for other children with the same genetic defect. Since then, more than 60 additional patients have been found. The disease affects every system of the body and is characterized by low muscle tone, seizures, developmental delays, and an inability to produce tears.

Sadly, Bertrand passed away in October at the age of 12. Although his life was cut short, his legacy will benefit children around the world. Through their website, NGLY1.org, Bertrands parents collect and share a wealth of research and family stories to help educate and inform the community. As more patients have been identified, its become apparent that even though the same gene is deactivated in all of them, their symptoms and severity of disease vary widely.

Geneticist Clement Chow, Ph.D., assistant professor in the Department of Human Genetics at University of Utah Health, studies NGLY1 deficiency in the fruit fly, Drosophila melanogaster. To understand how the disease symptoms can vary so much, he and his colleagues are hunting for other genes that interact with NGLY1. In a paper published in eLife, Chow reports that his lab has found that one of these interacting genes moderates disease severity. The gene, called ncc69, has a human counterpart called NKCC1. Their experiments showed that NGLY1 chemically modifies NKCC1. Studying this interaction could help illuminate how NGLY1 deficiency affects the body.

Common diseases, such as heart disease or cancer, arise from a combination of many genetic and environmental causes, while rare diseases are more likely caused by a single gene. But every single-gene disease occurs against the individual patients unique genetic backdrop, a patchwork of different genetic variants inherited from both parents. Children with NGLY1 deficiency start experiencing serious symptoms early in life, suggesting that environmental differences, such as diet, arent a key factor. More likely, differences in their other genes are influencing the clinical course of the disease.

To search for genes that work together with NGLY1, the researchers needed to use flies with varied genetic backgrounds. Laboratory flies, however, are inbred to be genetically identical. To approximate the natural genetic diversity found in humans, Chow turned to a resource called the Drosophila Genetic Reference Panel. Its a collection of 200 different fruit fly lines, all bred from the same original populationbut each one is just a bit different from the others.

Its like if you sampled 200 Northern Europeans, Chow says. Theyd share lots of genetic variants, but lots of differences as well.

In each strain of flies, Chow and his research team swapped in a non-working copy of the NGLY1 gene, then looked for differences in survival. Strikingly, the flies genetic background heavily influenced how long the young flies could survive without NGLY1.

These flies all carry the same disease mutation thats supposed to cause the same disease, Chow says. Yet here were seeing that, in some genetic backgrounds, they cant live at all with NGLY1 deficiency. And in some genetic backgrounds, all the flies survived to adulthood.

The researchers analyzed the genes that varied among the flies that survived and those that died, coming up with a list of candidate genes that could be playing a role. They began studying one of these candidates, NKCC1, and soon switched from flies to mice.

When we hit a wall in what we could do with flies, we decided to turn to the mouse model to try to fully characterize what NKCC1 and NGLY1 are doing to interact with each other, Chow says.

In cells from mice, the researchers discovered that the NKCC1 protein assumes its correct shape through glycosylation, a chemical process that tacks sugar molecules onto the protein. NGLY1 acts to remove these sugar molecules from specific targets.

In the absence of NGLY1, Chow found, NKCC1 was overloaded with extra sugars, reducing activity in the cell by 50%. Without NGLY1, NKCC1 cant do its job properly, which is to move fluids and ions out of the cell.

While application to human disease is still a long way off, the role of NKCC1 makes sense in terms of the symptoms seen in NGLY1 patients. One of the hallmark features of NGLY1 deficiency is the inability to make tears, sweat, and saliva. It turns out that patients who lack NKCC1 also have this symptom. NKCC1 is active in salivary glands, sweat glands, and tear ducts, which supports the idea that the molecule plays a role in causing the symptoms.

This was all discovered through a genetic screen in Drosophila, Chow says. This really speaks to the power of using simpler model organisms, especially for rare diseases, where you want to get results faster.

-Written by Caroline Seydel

# # #

In addition to U of U Health scientists, contributors include researchers from the University of Pittsburgh, The Jackson Laboratory and the Veterans Affairs Salt Lake City Health System.

The study published as A Drosophila screen identifies NKCC1 as a modifier of NGLY1 deficiency and was supported by the National Institutes of Health, Might Family, and the Glenn Foundation for Medical Research.

View original post here:
Partners in Crime: Genetic Collaborator May Influence Severity of the Rare Disease, NGLY1 - Newswise